PTO/SB/30 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Pagerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.				
Request For Continued Examination (RCE) Transmittal Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Application Number	10/034,237		
	Filing Date	December 27, 2001		
	First Named Inventor	Jyrki Hoisko		
	Art Unit	2616		
	Examiner Name	Jonathan, Liou		
	Attorney Docket Number	006474.00004		
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.  Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to				

June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2 Submission required under 37 C.F.R. 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_\_\_\_\_ b. . X Enclosed Amendment/Reply
Affidavit(s)/Declaration(s) iii. Information Disclosure Statement (IDS) iv. Dother\_\_ Miscellaneous a. Suspension of action on the above-identified application is requested under 37 C.F.R. 1.103(c) for a period of \_\_\_\_\_\_months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. 1.17(i) required) b. Other Fees The RCE fee under 37 C.F.R. 1.17(e) is required by 37 C.F.R. 1.114 when the RCE is filed. a. A The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 19-0733. I have enclosed a duplicate copy of this sheet. RCE fee required under 37 C.F.R. 1.17(e)
Extension of time fee (37 C.F.R. 1.136 and 1.17)
Other b. Check in the amount of \$ enclosed c. Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not be included on this form.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
Signature	/Steve S. Chang/	Date	October 9, 2006		
Name (Print /Type)	Steve S. Chang	Registration No. (Attorney/Agent)	42,402		
CERTIFICATE OF MAILING OR TRANSMISSION					

Provide credit card information and authorization on PTO-2038.

CENTIFICATE OF MAILING ON TRANSMISSION					
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.					
Signature					
Name (Print /Type)		Date			

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Cifficer, U.S. Patient and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND.